IRIS
TROIANI, Teresa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.710
NA - Nord America 4.623
AS - Asia 4.554
SA - Sud America 782
AF - Africa 71
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 3
Totale 22.760
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 8.543
US - Stati Uniti d'America 4.537
SG - Singapore 1.688
IE - Irlanda 1.232
CN - Cina 1.001
IT - Italia 921
HK - Hong Kong 778
BR - Brasile 651
DE - Germania 435
GB - Regno Unito 411
UA - Ucraina 352
KR - Corea 312
FR - Francia 251
VN - Vietnam 250
FI - Finlandia 137
IN - India 135
SE - Svezia 124
JP - Giappone 113
GR - Grecia 108
TR - Turchia 85
CA - Canada 52
AR - Argentina 51
PK - Pakistan 42
NL - Olanda 40
AT - Austria 33
BD - Bangladesh 30
BE - Belgio 29
EC - Ecuador 26
ID - Indonesia 26
MX - Messico 24
ES - Italia 20
ZA - Sudafrica 20
CZ - Repubblica Ceca 17
CO - Colombia 16
IQ - Iraq 16
MA - Marocco 15
PL - Polonia 15
AZ - Azerbaigian 10
CL - Cile 10
IL - Israele 10
AU - Australia 9
IR - Iran 8
NZ - Nuova Zelanda 8
PE - Perù 8
CH - Svizzera 7
KE - Kenya 6
LT - Lituania 6
PY - Paraguay 6
VE - Venezuela 6
BJ - Benin 5
JO - Giordania 5
KG - Kirghizistan 5
TN - Tunisia 5
UZ - Uzbekistan 5
AL - Albania 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
EG - Egitto 4
HU - Ungheria 4
KZ - Kazakistan 4
MK - Macedonia 4
RO - Romania 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
ET - Etiopia 3
NP - Nepal 3
PH - Filippine 3
SA - Arabia Saudita 3
SN - Senegal 3
TH - Thailandia 3
BH - Bahrain 2
DZ - Algeria 2
EU - Europa 2
GA - Gabon 2
GI - Gibilterra 2
HN - Honduras 2
LK - Sri Lanka 2
LV - Lettonia 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CV - Capo Verde 1
GE - Georgia 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MD - Moldavia 1
MY - Malesia 1
NG - Nigeria 1
OM - Oman 1
Totale 22.753
Salva come PNG Salva come JPEG
Città #
Moscow 2.998
Dublin 1.217
Hong Kong 775
Singapore 733
Santa Clara 724
Chandler 669
Jacksonville 561
Seoul 292
Beijing 175
Naples 162
Princeton 162
Hefei 160
New York 160
Ashburn 143
Bremen 138
Dallas 137
Roxbury 129
Medford 121
Ann Arbor 120
Munich 103
The Dalles 93
Bengaluru 84
Ho Chi Minh City 81
Caserta 79
Wilmington 72
São Paulo 70
Los Angeles 63
Boardman 58
Cambridge 47
Nanjing 47
Hanoi 44
San Mateo 43
Des Moines 42
Woodbridge 38
Turku 37
Elora 34
Milan 34
Napoli 34
Nuremberg 32
Brussels 29
Dong Ket 22
Rio de Janeiro 22
Tianjin 22
Houston 21
Amsterdam 18
Brooklyn 18
Falkenstein 17
Mountain View 17
Shanghai 17
Vienna 17
Brno 16
Brasília 15
Nanchang 15
Norwalk 15
Rome 15
Tokyo 15
Aversa 14
Columbus 14
Haiphong 14
Jakarta 13
Lappeenranta 13
Rawalpindi 13
Warsaw 13
Belo Horizonte 12
Helsinki 12
Jinan 12
London 12
San Francisco 12
Changsha 11
Council Bluffs 11
Ercolano 11
Hangzhou 11
Istanbul 11
Baku 10
Guangzhou 10
Hải Dương 10
Atlanta 9
Bogotá 9
Chicago 9
Curitiba 9
Düsseldorf 9
Zhengzhou 9
Bahawalpur 8
Boston 8
Campinas 8
Cape Town 8
Castello di Brianza 8
Changchun 8
Da Nang 8
Guayaquil 8
Johannesburg 8
Kunming 8
Madrid 8
Manchester 8
Redwood City 8
Seattle 8
Baghdad 7
Cava Dei Tirreni 7
Mauá 7
Phoenix 7
Totale 11.455
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 221
ONCOLOGIA MEDICA 197
Beyond N staging in colorectal cancer: Current approaches and future perspectives 196
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 192
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 173
AXL is an oncotarget in human colorectal cancer 172
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 168
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 165
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 164
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 164
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 162
A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells 161
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 161
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 158
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 157
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 157
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 156
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 154
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry 150
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 149
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 147
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 146
A preliminary study for quantitative assessment with HFUS (High-frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: Interdisciplinary team experience 146
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 145
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 145
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 144
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 144
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 144
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 143
Cytologic diagnosis of metastatic melanoma by FNA: A practical review 140
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 140
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 139
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 138
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 138
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 138
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 137
Small Bowel Metastasis in a Stage IV Melanoma Patient: A Report of Multimodal Approach 137
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 136
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 135
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 134
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 134
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 134
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 134
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 133
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 132
Antiangiogenic drugs in non small cell lung cancer treatment 132
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 130
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 130
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass 128
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 128
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 128
Farmacogenomica e cancro colorettale 127
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 126
To Get the Most out of the Least: BRAF Molecular Evaluation in Melanoma Metastases on Cell Suspension from Fine Needle Aspiration Cytology Needle Rinses 125
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 125
TRASTUZUMAB RESISTANCE IN BREAST CANCER 125
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 125
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines 124
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 124
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 123
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 123
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review 122
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 122
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 121
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 121
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 121
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 120
The potential diagnostic and predictive role of anaplastic lymphoma kinase (ALK) gene alterations in melanocytic tumors 120
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 119
Targeting EGFR in Pancreatic Cancer Treatment. 117
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 117
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 117
Application of CytoMatrix for the diagnosis of melanoma metastases on FNA cytology samples: Performance of a novel cell block method 116
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 116
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 114
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 113
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 113
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 113
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 112
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 112
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 111
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 110
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 110
Therapeutic integration of signal trasdution targeting agents an conventional anticancer treatments 110
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 110
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model 109
Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis 109
Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients 109
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 109
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 109
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 108
Pimasertib hydrochloride 108
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 108
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 106
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 106
Metformin in lung cancer: rationale for a combination therapy 105
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 105
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 105
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 105
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 105
Totale 13.266
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.941
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021563 0 0 0 0 0 25 119 96 29 115 124 55
2021/20221.163 57 26 27 25 340 25 37 35 57 90 120 324
2022/20232.567 255 56 46 237 283 233 10 158 1.150 14 71 54
2023/20241.111 102 49 40 67 329 171 33 33 21 16 86 164
2024/20253.522 61 93 47 139 527 462 453 328 466 379 308 259
2025/202612.106 609 716 748 734 1.213 8.086 0 0 0 0 0 0
Totale 23.254